Modality
mAb
MOA
BETi
Target
PLK4
Pathway
Apoptosis
Huntington's
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
Dec 2017
→ Jun 2028
Phase 1Current
NCT07268402
233 pts·Huntington's
2017-12→2028-06·Terminated
233 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-06-012.2y awayInterim· Huntington's
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1
Termina…
Catalysts
Interim
2028-06-01 · 2.2y away
Huntington's
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07268402 | Phase 1 | Huntington's | Terminated | 233 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Pexaosocimab | United Therapeutics | NDA/BLA | PLK4 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 |